Interestingly, while all BYL‐719‐treated tumours presented a significant decrease in CD206 staining, the effects on CD4 and CD8 immune cell population were found heterogeneous; this is associated with the fact that some BYL‐719‐treated mice presented (albeit in a reduced size and number) macro‐metastatic foci. The gene discussed is CD8A; the disease is neoplasm.